Samsung Biologics takes on manufacturing duties for GreenLight's Covid-19 vaccine - Endpoints News

Sam­sung Bi­o­log­ics has en­tered an agree­ment with biotech Green­Light Bio­Sciences to man­u­fac­ture its mR­NA Covid-19 vac­cine at com­mer­cial scale, the two com­pa­nies an­nounced.

Sam­sung Bi­o­log­ics, one of the fastest grow­ing man­u­fac­tur­ers in the world right now, will use its vac­cine man­u­fac­tur­ing ex­per­tise to help pa­tients in low­er-in­come coun­tries, CEO John Rim said in a press re­lease. This will help ex­pand their ca­pa­bil­i­ties from drug sub­stance to asep­tic fill-fin­ish and all the way to com­mer­cial re­lease from one site.

“At this time of ur­gent glob­al de­mand, we will strive for seam­less ser­vice across our bio­man­u­fac­tur­ing net­work to fight the COVID pan­dem­ic and in turn, help make progress to­wards Ko­rea’s vac­cine hub goal,” he said in a press re­lease.

Sam­sung’s Song­do fa­cil­i­ty will be ready for cGMP op­er­a­tions in ear­ly 2022, the com­pa­ny said. It added drug sub­stance ca­pa­bil­i­ties to the site ear­li­er this year, in an at­tempt to be proac­tive in ac­com­mo­dat­ing clients’ needs.

In Au­gust, Green­light re­verse-merged its way on­to the Nas­daq, land­ing a $1.5 bil­lion val­u­a­tion af­ter merg­ing with the SPAC En­vi­ron­men­tal Im­pact Ac­qui­si­tion Corp., which is backed by Canac­cord Ge­nu­ity Group and Hud­son Bay Cap­i­tal Man­age­ment. That merg­er land­ed the com­pa­ny $207 mil­lion and $105 mil­lion in PIPE fi­nanc­ing.

The com­pa­ny was found­ed in 2008 to use its mR­NA tech­nol­o­gy to pro­tect both hu­mans and agri­cul­ture, in­clud­ing hon­ey­bees and crops. It was vir­tu­al­ly un­known be­fore the merg­er. Now, the com­pa­ny is look­ing to set up a blue­print for vac­ci­nat­ing the world from Covid-19, and hopes to do so through im­proved mR­NA man­u­fac­tur­ing ca­pa­bil­i­ties. It’s been work­ing on sea­son­al flu and sick­le cell dis­ease vac­cines as well, but it got its start while try­ing to shake up the pes­ti­cides mar­ket for in­dus­tri­al agri­cul­ture.

“There is an ur­gent need to de­vel­op vac­cines for the whole world,” Green­Light CEO An­drey Zarur said in a press re­lease. “Our vac­cine tri­al will open the way to make vac­cines that are avail­able to every­body, not just cit­i­zens of de­vel­oped coun­tries.”

There are cur­rent­ly three plants at the Sam­sung Song­do cam­pus. A fourth is on the way, and the CD­MO just got ap­proved to build a fifth in No­vem­ber.

Sam­sung will fin­ish the $259 mil­lion site on 32,808-square-feet of land in the city, which comes on the heels of its newest cell line, which launched in Au­gust 2020. It’s al­so in talks to ac­quire more land to de­vel­op a sec­ond bio com­plex. This, and all of Sam­sung’s oth­er ex­pan­sions, come on the heels of a 64% in­crease in sales from last year to $375 mil­lion, large­ly thanks to an in­creased de­mand for CD­MO ser­vices.

A pre­vi­ous ver­sion of this sto­ry stat­ed that Green­Light was based in South Ko­rea. It is based out of Boston, MA.

Adblock test (Why?)

Read Again https://endpts.com/samsung-biologics-takes-on-manufacturing-duties-for-greenlights-covid-19-vaccine/

Bagikan Berita Ini